COMP <GO>
CLPT vs INFU // REVENUE GROWTH (YOY)
ClearPoint Neuro Inc. (NASDAQ) VS. InfuSystems Holdings Inc. (NYSE) • 15-METRIC TALLY: CLPT 3
— INFU 7
▲ REVENUE GROWTH (YOY) LEADER: CLPT
LAST: $10.67 (-0.19%) • MKT CAP: $342.7M
revenue-growth
17.80%
LAST: $14.07 (-2.63%) • MKT CAP: $287.8M
revenue-growth
6.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLPT VS. INFU)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLPT | INFU | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.40% | 56.00% | +5.40 | CLPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 12.80% | -47.80 | INFU | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 24.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.13% | 8.29% | -15.42 | INFU | /fcf-yield <GO> |
| Operating Margin | -60.00% | 8.30% | -68.30 | INFU | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 4.60% | -64.60 | INFU | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 17.80% | 6.40% | +11.40 | CLPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.16 | -4.96 | INFU | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | INFU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 63.5 | -14.40 | INFU | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 40.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $342.7M | $287.8M | $54.9M | CLPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLPT REV | INFU REV | CLPT GROSS % | INFU GROSS % | CLPT FCF | INFU FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $37.0M | $143.4M | 61.4% | 56.0% | -$24.4M | $23.8M |
| FY 2024 | $31.4M | $134.9M | 60.9% | 52.2% | -$9.2M | $19.4M |
| FY 2023 | $24.0M | $125.8M | — | — | -$13.7M | $11.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLPT // BETA —
INFU // BETA —